Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
about
An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesOld and new treatment targets in axial spondyloarthritisNew treatment targets for axial spondyloarthritisShould axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Advances in managing ankylosing spondylitisSpontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisMaintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).Biological therapies for spondyloarthritis.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Looking into the new ASAS classification criteria for axial spondyloarthritis through the other side of the glass.Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes.Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis.Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.Are Additional Tests Needed to Rule Out Axial Spondyloarthritis in Patients Ages 16-45 Years With Short-Duration Chronic Back Pain and Maximally One Spondyloarthritis Feature?Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients.Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis.The window of opportunity: a relevant concept for axial spondyloarthritis.Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort.Patient Burden of Axial Spondyloarthritis.Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials.[Spondyloarthritides].Brief Report: Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints.Identifying axial spondyloarthritis in Dutch primary care patients, ages 20-45 years, with chronic low back pain.Juvenile Spondyloarthropathies.Low Rate of Progression to Ankylosing Spondylitis Among Patients With Presumed Nonradiographic Axial Spondyloarthritis: Comment on the Article by Wang et al.Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with EarlAxial spondyloarthritis.The concept of axial spondyloarthritis. Lessons from the INFAST study.Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
P2860
Q26741170-DA13599F-2F02-45BC-88AE-8D39FE0654BEQ26777084-D9DD1D55-5CE3-4F6B-B255-BA9C08D490F4Q26777906-D521C55E-2091-48C2-9C3D-45627B54CF43Q28073999-607638BE-285C-46C2-BB6B-57A8990720ADQ30239856-2806D358-B223-40D9-B8CD-DD6D529D17B9Q30240183-97A65F99-B212-4F72-A32B-0EFF5EE678FCQ30240212-BC829D66-037A-46F3-8B5C-C1D0782731A5Q34201927-54DB306B-53B0-4EDF-B001-9C1A1CE01AEEQ34894874-0D9C099B-1C7A-48C7-93B9-E7EF2B65897AQ36321264-F2892F80-B7FA-42A1-B65B-A1DA36B6D509Q36584217-A4E72DEC-4AE2-4CCE-AA20-4F106E7BD2AEQ37465472-07FD5DE4-3BCB-4AE7-8032-A8EF70F0FF9AQ37690041-F875541E-8FC2-4CBB-A438-3A70A7B869BFQ38198090-DA6B3A79-B944-4A5C-85F8-B4A0A009FDE3Q38199786-998A2804-6E86-4361-B7F5-35978F99268AQ38217223-77FA06AB-281E-4AAF-9F63-BD6E8F5636E4Q38365041-E403905C-27C7-4978-A5DC-A7DB33B3A8E5Q38447791-150802E0-0E69-4F04-83FC-B9552D298F1CQ38517691-EBF89F19-85C6-4071-8497-C4B1AA32EBD8Q38780258-6A495679-DF21-49CD-AC92-5FC470BBFB29Q38914839-F842F7F5-6D8A-4630-B0AB-A0A296193C60Q38972623-45B47068-B82D-482E-9E59-72C159F63782Q39135959-037D8456-C344-4499-AB25-08DEA450F5C9Q39909425-078B3755-EC2C-4FB8-A6CB-953C781AF015Q40042219-578E5514-0042-4E26-A144-9F5A5EFC49E5Q40204477-1D774CBA-4A00-4160-9665-D5423F2C7E4BQ40554011-165E2D17-6ED5-4A3A-B4A1-02EEC6C1B54FQ40791296-E61708D3-F88C-436E-B2A3-D2243B40CC42Q42292173-0A89CD7E-BCC7-4309-A591-C4F6DDCB9F3EQ42365374-80B75043-E3AE-4411-9B57-066A864DEF3AQ42376342-DC7DDDC6-3395-4936-A51C-A5DBE611634EQ48512693-C65E79FB-D7BB-490F-AF42-E1CBB6BC6418Q48931896-786EF651-6CB6-456D-BB79-723C4F78019EQ51159770-682A04F6-35E8-4C7E-A54C-FA1E68ED471EQ51648725-44D6D310-3AAA-4FEB-87BB-39F18DDA89FDQ52844783-5D50D75F-E612-49FC-8424-833AC4626089Q52854518-51719510-895A-4123-B553-687FA75E7343Q52870848-7E142340-D945-4DA1-93C6-80C4DF45F4BCQ54472337-2C20E0D3-C59E-42F7-8EC5-652A407B7F61Q54624586-41EEEADE-D3E6-4097-BD77-410DE6C0A134
P2860
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of inflixi ...... ontrolled INFAST study, Part 1
@en
Efficacy and safety of inflixi ...... ntrolled INFAST study, Part 1.
@nl
type
label
Efficacy and safety of inflixi ...... ontrolled INFAST study, Part 1
@en
Efficacy and safety of inflixi ...... ntrolled INFAST study, Part 1.
@nl
prefLabel
Efficacy and safety of inflixi ...... ontrolled INFAST study, Part 1
@en
Efficacy and safety of inflixi ...... ntrolled INFAST study, Part 1.
@nl
P2093
P2860
P1476
Efficacy and safety of inflixi ...... ontrolled INFAST study, Part 1
@en
P2093
All INFAST Investigators
D Chitkara
J Lenaerts
J Wollenhaupt
L Myasoutova
M Rudwaleit
N Vastesaeger
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-203201
P407
P50
P577
2013-05-21T00:00:00Z